NASDAQ : QURE
uniQure N.V. — Key statistics
Healthcare · Biotechnology · Netherlands
Last price 24.83 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.72B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.59B |
| Enterprise Value | 1.34B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 69.37M |
| Shares Outstanding | 69.37M |
| Shares Change (YoY) | +20.93% |
| Shares Change (QoQ) | +5.58% |
| Owned by Insiders (%) | 1.69% |
| Owned by Institutions (%) | 81.91% |
| Float | 57.53M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 85.33 |
| Forward PS | 39.32 |
| PB Ratio | 4.91 |
| P/TBV Ratio | 6.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 71.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.01 |
| Quick Ratio | 9.79 |
| Debt / Equity | 1.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.31 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -157.61% |
| Return on Assets (ROA) | -15.72% |
| Return on Invested Capital (ROIC) | -226.44% |
| Return on Capital Employed (ROCE) | -21.89% |
| Weighted Average Cost of Capital (WACC) | 9.68% |
| Revenue Per Employee | $84,489 |
| Profits Per Employee | -$1.14M |
| Employee Count | 221 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 7.04M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.06 |
| 52-Week Price Change | -66.07% |
| 50-Day Moving Average | 34.05 |
| 200-Day Moving Average | 29.66 |
| Relative Strength Index (RSI) | 36.78 |
| Average Volume (20 Days) | 1,937,399 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.73M |
| Short Previous Month | 8.72M |
| Short % of Shares Out | 12.58% |
| Short % of Float | 15.17% |
| Short Ratio (days to cover) | 2.55 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 18.67M |
| Gross Profit | -114.71M |
| Operating Income | -197.38M |
| Pretax Income | -245.17M |
| Net Income | -252.21M |
| EBITDA | -182.92M |
| EBIT | -197.38M |
| Loss Per Share | -$4.04 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 810.34M |
| Total Debt | 552.17M |
| Net Cash | 258.17M |
| Net Cash Per Share | $3.72 |
| Equity (Book Value) | 324.05M |
| Book Value Per Share | 4.67 |
| Working Capital | 750.92M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -160.79M |
| Capital Expenditures | -665,000 |
| Depreciation & Amortization | 14.47M |
| Net Borrowing | n/a |
| Free Cash Flow | -161.45M |
| FCF Per Share | -$2.33 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,057.10% |
| Pretax Margin | -1,313.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.93% |
| Shareholder Yield | -20.93% |
| Earnings Yield | -17.57% |
| FCF Yield | -10.13% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $60.36 |
| Price Target Difference | 162.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 185.97% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.37 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |